AU2014306956B2 - Methods for reducing exacerbation rates of asthma using benralizumab - Google Patents

Methods for reducing exacerbation rates of asthma using benralizumab Download PDF

Info

Publication number
AU2014306956B2
AU2014306956B2 AU2014306956A AU2014306956A AU2014306956B2 AU 2014306956 B2 AU2014306956 B2 AU 2014306956B2 AU 2014306956 A AU2014306956 A AU 2014306956A AU 2014306956 A AU2014306956 A AU 2014306956A AU 2014306956 B2 AU2014306956 B2 AU 2014306956B2
Authority
AU
Australia
Prior art keywords
asthma
methods
benralizumab
exacerbation rates
reducing exacerbation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014306956A
Other languages
English (en)
Other versions
AU2014306956A1 (en
Inventor
Donald Raible
Lorin Roskos
Bing Wang
Christine Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2014306956A1 publication Critical patent/AU2014306956A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: MEDLMMUNE, LLC
Application granted granted Critical
Publication of AU2014306956B2 publication Critical patent/AU2014306956B2/en
Priority to AU2020201327A priority Critical patent/AU2020201327A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
AU2014306956A 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab Active AU2014306956B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201327A AU2020201327A1 (en) 2013-08-12 2020-02-24 Methods for reducing exacerbation rates of asthma using benralizumab

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
US61/864,944 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201327A Division AU2020201327A1 (en) 2013-08-12 2020-02-24 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (2)

Publication Number Publication Date
AU2014306956A1 AU2014306956A1 (en) 2016-02-04
AU2014306956B2 true AU2014306956B2 (en) 2019-11-21

Family

ID=52448837

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014306956A Active AU2014306956B2 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab
AU2020201327A Abandoned AU2020201327A1 (en) 2013-08-12 2020-02-24 Methods for reducing exacerbation rates of asthma using benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201327A Abandoned AU2020201327A1 (en) 2013-08-12 2020-02-24 Methods for reducing exacerbation rates of asthma using benralizumab

Country Status (26)

Country Link
US (2) US9441037B2 (https=)
EP (1) EP3033101B1 (https=)
JP (4) JP6746495B2 (https=)
KR (2) KR20220057637A (https=)
CN (2) CN105451760A (https=)
AU (2) AU2014306956B2 (https=)
BR (1) BR112016002401A8 (https=)
CA (1) CA2918105C (https=)
CY (1) CY1122132T1 (https=)
DK (1) DK3033101T3 (https=)
ES (1) ES2716906T3 (https=)
HK (1) HK1221644A1 (https=)
HR (1) HRP20190405T1 (https=)
HU (1) HUE042607T2 (https=)
LT (1) LT3033101T (https=)
ME (1) ME03348B (https=)
MX (1) MX368508B (https=)
PL (1) PL3033101T3 (https=)
PT (1) PT3033101T (https=)
RS (1) RS58404B1 (https=)
RU (1) RU2676333C2 (https=)
SG (2) SG10202005560UA (https=)
SI (1) SI3033101T1 (https=)
SM (1) SMT201900163T1 (https=)
TR (1) TR201903312T4 (https=)
WO (1) WO2015023504A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
EP3371225A2 (en) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3565823B1 (en) 2017-01-04 2024-05-29 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291073A1 (en) * 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｉｌ－５受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
AU2010322066A1 (en) * 2009-11-18 2012-06-21 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
RU2728578C2 (ru) 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291073A1 (en) * 2007-05-14 2010-11-18 Medimmune, Llc Methods of reducing eosinophil levels
US20120328606A1 (en) * 2011-05-18 2012-12-27 Medimmune, Llc Methods Of Diagnosing And Treating Pulmonary Diseases Or Disorders
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS GOV, "A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563", INTERNET CITATION, (2008-10-03), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/show/NCT00768079, (2015-03-17) *
CLINICALTRIALS GOV, "Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting [beta]2 Agonist , URL: https://clinicaltrials.gov/show/NCT01914757, (2017-02-03) *
Kolbeck et al. (2010), J. Allergy Clin Immunol., vol. 125pp. 1344-1353. *

Also Published As

Publication number Publication date
EP3033101A4 (en) 2017-07-12
MX368508B (es) 2019-10-07
JP2022120009A (ja) 2022-08-17
PT3033101T (pt) 2019-04-02
ES2716906T3 (es) 2019-06-17
DK3033101T3 (en) 2019-04-08
BR112016002401A8 (pt) 2018-06-12
RU2016108723A (ru) 2017-09-19
HK1225302B (en) 2017-09-08
MX2016001383A (es) 2016-08-03
LT3033101T (lt) 2019-03-25
US20170198049A1 (en) 2017-07-13
KR102390714B1 (ko) 2022-04-26
JP2024129139A (ja) 2024-09-26
SI3033101T1 (sl) 2019-04-30
HRP20190405T1 (hr) 2019-04-19
BR112016002401A2 (pt) 2017-09-12
CN105451760A (zh) 2016-03-30
KR20220057637A (ko) 2022-05-09
SG10202005560UA (en) 2020-07-29
US20150044202A1 (en) 2015-02-12
RU2016108723A3 (https=) 2018-06-18
KR20160042121A (ko) 2016-04-18
WO2015023504A8 (en) 2015-09-24
HK1221644A1 (zh) 2017-06-09
CA2918105C (en) 2023-02-28
JP2020128375A (ja) 2020-08-27
CY1122132T1 (el) 2020-11-25
SG11201600481UA (en) 2016-02-26
PL3033101T3 (pl) 2019-06-28
SMT201900163T1 (it) 2019-05-10
JP6746495B2 (ja) 2020-08-26
RU2676333C2 (ru) 2018-12-28
AU2020201327A1 (en) 2020-03-12
TR201903312T4 (tr) 2019-04-22
EP3033101B1 (en) 2018-12-19
US9441037B2 (en) 2016-09-13
WO2015023504A1 (en) 2015-02-19
AU2014306956A1 (en) 2016-02-04
EP3033101A1 (en) 2016-06-22
HUE042607T2 (hu) 2019-07-29
ME03348B (me) 2019-10-20
CN111588848A (zh) 2020-08-28
RS58404B1 (sr) 2019-04-30
CA2918105A1 (en) 2015-02-19
JP2016527324A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
EP4406610A3 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP4036240A3 (en) Transduction buffer
SG194701A1 (en) Anti-cd40 antibodies and methods of use
WO2015006571A8 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
PH12014502406B1 (en) Anti-il-23p19 antibodies
MY155950A (en) Anti-cd40 antibodies
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
PH12016501366A1 (en) Novel anti-baff antibodies
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX347164B (es) Anticuerpos anti-il-36r.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EP4306174A3 (en) Composition for controlled ovarian stimulation
MX2014004968A (es) Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma.
MX360774B (es) Antagonistas de progesterona.
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): MEDLMMUNE, LLC

FGA Letters patent sealed or granted (standard patent)